Talk:Imiquimod
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Imiquimod.
|
| This is the talk page for discussing improvements to the Imiquimod article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 3 months  |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
Note
editwent through and cleaned up this article today. MEDMOS, sourcing, etc. also manually archived old talk cruft. Jytdog (talk) 19:16, 14 June 2015 (UTC)
Imiquimod as a vaccine adjuvant
editWould it be beneficial to verify these items and get DOI for imiquimod making some vaccines 40-80% more effective, including malaria and TB, two of the 10 most lethal infectious diseases? What do you suggest?
The nonsentient AI chatGPT Scholar, says:2. Imiquimod in Malaria Vaccines Topical Imiquimod: In preclinical studies, topical administration of imiquimod enhanced antibody titers and cellular immunity. It was tested as an adjunct to the AMA1-C1/alum malaria vaccine. Efficacy: Increased IFN-γ and antigen-specific T-cell responses by 40–60% compared to vaccine alone. Improved survival in challenge studies by up to 30%. Combination Adjuvants: Imiquimod was tested alongside other adjuvants, such as AS01, in subunit malaria vaccines. Enhanced long-term immunity and antibody affinity by 25–50%. Reference: Frontiers in Immunology.
3. Imiquimod in Tuberculosis Vaccines Chimeric DNA Vaccines: Imiquimod has been tested in combination with chimeric TB vaccines to enhance the recruitment of immune cells. Effectiveness: Increased Th1 cytokine production (IL-2, IFN-γ) by 60–80% in preclinical models. Enhanced memory T-cell formation, critical for long-term protection. Imiquimod + CpG ODN: Combined with CpG oligodeoxynucleotides, imiquimod improved macrophage activation and granuloma formation. Efficacy: Reduced bacterial load in lungs by 2-fold compared to non-adjuvanted vaccines. Reference: Immunohorizons.
4. Comparative Efficacy Vaccine Adjuvant Efficacy Improvement Mechanism Malaria (AMA1-C1) Imiquimod + alum 40–60% Th1 response Increased IFN-γ, antigen-specific T-cells Malaria (RTS,S) Imiquimod + AS01 25–50% antibody affinity Enhanced antibody durability Tuberculosis (DNA) Imiquimod + CpG ODN 2x bacterial clearance Synergistic macrophage activation Tuberculosis (Chimeric) Imiquimod 60–80% Th1 cytokines Boosted IL-12, IFN-γ 5. Limitations Toxicity: High doses of imiquimod may cause excessive local inflammation. Efficacy Variability: Combination with other adjuvants (e.g., alum, AS01) often required for optimal results. Clinical Translation: While promising in preclinical models, human trials are limited. 6. Future Directions Incorporation of imiquimod in nanoparticle or liposomal delivery systems to reduce toxicity and enhance efficacy. Use in combination with broader immune stimulants for multidrug-resistant TB and severe malaria. " — Preceding unsigned comment added by Treonsverdery (talk • contribs) 06:20, 1 December 2024 (UTC)